Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced the initiation of its first U.S.-based Phase 1/2a trial of CMND-100 in alcohol use disorder (AUD) at the Johns Hopkins University School of Medicine.
According to Clearmind, the first in human clinical trial will investigate the safety, tolerability and full pharmacokinetic profile of Clearmind’s proprietary MEAI-based oral drug candidate, CMND-100, developed as a breakthrough treatment for AUD patients. The study will also include preliminary efficacy evaluations, examining the drug’s potential to reduce alcohol cravings and consumption.
The study will be led by the principal investigator, Jennifer Ellis, Ph.D., associate professor of psychiatry and behavioral sciences, JHU School of Medicine and by co-investigator professor Eric Strain, director, Behavioral Pharmacology Research Unit, JHU School of Medicine. In addition to Johns Hopkins University School of Medicine, Maryland, USA, the trial will be conducted at Yale School of Medicine’s Department of Psychiatry, Connecticut, and IMCA Center, Ramat-Gan, Israel.
In a statement, Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, “The initiation of our clinical trial at Johns Hopkins, one of the most respected research institutions in the world, is a significant step in our journey toward FDA approval. The involvement of such esteemed clinical sites in our clinical trial reflects the growing recognition of CMND-100’s potential as a breakthrough treatment for AUD. With additional clinical sites launching the trial including Yale and IMCA in Israel, we are establishing a strong foundation to evaluate the clinical potential of our psychedelic-based therapeutic platform.”
